Asterion is a vertically-integrated Canadian cannabis company focused on its operations in Australia. With the goal of being a leader in precision agriculture, the company is working on producing high-quality, low-cost and genetically-uniform cannabis strains and products. To achieve this goal, Asterion is developing a 4.3 million-square-foot pharmaceutical-grade medical cannabis facility in Southeast Queensland, Australia. Once fully developed, the facility will produce over 500,000 kilograms of cannabis annually.
Further establishing a footprint in Australia, the company has aligned itself with PreveCeutical Medical Inc. (CSE:PREV,OTCQB:PRVCF,FWB:18H), a preventive health sciences company focused on developing preventive medicine, to develop new cannabis-based preventive and curative therapies.
Asterion’s company highlights include the following:
- Developing a state-of-the-art 4.3-million-square-foot facility in Southeast Queensland, Australia.
- Southeast Queensland receives over 2,400 hours of sunlight annually.
- Will plant first cannabis crop after Phase 1 of construction is complete.
- Projected annual production of over 500,000 kilograms of cannabis once operational.
- Future product lines may include tinctures, oils, edibles, flower and gelatin capsules.
- Awaiting approval for cultivation and sales licenses.
- Strategic partnerships in place with PreveCeutical and White Sheep Corp.
- Management has over 120 years of combined experience in medical cannabis, renewable energy, capital markets, among other sectors across the globe.
American cannabis sales hit US$17.5 billion in 2020, a research group’s new study shows.
Meanwhile, a Canadian cannabis producer began offering CBD beverages in the US, another move that shows how interested Canadians are in the overall US cannabis market at the moment.
Some pretty important news out of health and wellness; beverage and natural products company BevCanna Enterprises Inc. (CSE:BEV, Q:BVNNF, FSE:7BC) this week. For those of you following the Company with us, stay tuned.
As investors continue to prioritize cannabis opportunities in the US, market watchers expect mergers and acquisitions (M&A) to play a role in the future for Canadian companies.
A consolidation trend has been expected in the Canadian cannabis space for some time now based on the size of the market compared to the number of operations in the country.
BioHarvest Sciences Inc. Unveils the Unique Polyphenolic Content of Its Upcoming Olive-Based Nutraceutical
The product will include polyphenols known to have significant health benefits.
BioHarvest Sciences Inc. (CSE: BHSC) (“BioHarvest” or the “Company”) has reached an important milestone in its development program of additional Nutraceuticals. The olive-based Nutraceutical product scheduled for market availability in the second half of 2022 will contain the following unique matrix of polyphenols: hydroxytyrosol, trosol, and verbascoside. These compounds are the major polyphenols in naturally grown olives and are responsible for the high antioxidant activity of olives and olive oil. Importantly, the BioHarvest olive-based Nutraceutical product will provide all the benefits of olives and olive oil with a low calorie count per serving.
Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today that it will report financial results for the fourth quarter and full year ended December 31 st , 2020 on Thursday March 25 th , 2021 before the market opens.
The Company will host a conference call and webcast to discuss its financial results and provide investors with key business highlights on Thursday March 25 th , 2021 at 8:30am Eastern Time (7:30am Central Time).